靶点说明
UL123 (316-324) VLEETSVML HLA-A*02:01
HLA类型
抗原和HLA的亲和力
NetMHCpan 4.1 计算VLEETSVML与HLA-A*02:01亲和力为 89.11 nM，为稳定结合。
产品类型和应用
| 产品类型 | 规格 | 价格 |
| 流式检测与分选 | UL123 (316-324) HLA-A*02:01 PE / APC / Alexa Fluor 488 | 7200元/50ug, 11800元/100ug |
| 磁珠分选 | UL123 (316-324) HLA-A*02:01 HLA-A*02:01磁珠 | 8200元/50ug, 12800元/100ug |
| 生物素化复合物 | UL123 (316-324) HLA-A*02:01 HLA-A*02:01-biotin | 6800元/50ug, 11400元/100ug |
实测结果
肽刺激PBMC后检测抗原特异性CD8+T细胞
VLEETSVML多肽刺激HLA-A*02:01限制性PBMC后，使用UL123 (316-324) HLA-A*02:01 PE 四聚体和抗CD8-FITC抗体检测。下图左图为抗原肽VLEETSVML刺激组，右图为未加抗原肽刺激组。
靶点结合的TCR序列
请查看IEDB数据库
| Receptor – IEDB Receptor ID | Chain 1 – Calculated V Gene | Chain 1 – Calculated D Gene | Chain 1 – Calculated J Gene | Chain 1 – CDR3 Curated | Chain 2 – Calculated V Gene | Chain 2 – Calculated D Gene | Chain 2 – Calculated J Gene | Chain 2 – CDR3 Curated |
|---|---|---|---|---|---|---|---|---|
| 209258 | CVVRTDKLIF | CASSLDSQSSGNTIYF | ||||||
| 225171 | TRAV23/DV6 | TRAJ48 | CAASIGAFGNEKLTF | TRBV3-1 | TRBJ1-5 | CASSQVFGTPTPQHF | ||
| 225271 | TRAV5 | TRAJ13 | CAERGSGGYQKVTF | TRBV7-8 | TRBJ1-2 | CASSLKSPGQANWYGYTF | ||
| 225292 | TRAV12-1 | TRAJ11 | CVVRYSTLTF | TRBV5-1 | TRBJ1-3 | CASSADSIGSGNTIYF | ||
| 225397 | TRAV19 | TRAJ23 | CALSEYNQGGKLIF | TRBV3-1 | TRBJ1-5 | CASSQVFGTPTPQHF | ||
| 225401 | TRAV38-2/DV8 | TRAJ43 | CAYQWGGDMRF | TRBV3-1 | TRBJ1-5 | CASSQVFGTPTPQHF | ||
| 225405 | TRAV30 | TRAJ38 | CGTEGAGNNRKLIW | TRBV3-1 | TRBJ1-5 | CASSQVFGTPTPQHF | ||
| 225405 | TRAV30 | TRAJ38 | CGTEGAGNNRKLIW | TRBV3-1 | TRBJ1-5 | CASSQVFGTPTPQHF | ||
| 225405 | TRAV30 | TRAJ38 | CGTEGAGNNRKLIW | TRBV3-1 | TRBJ1-5 | CASSQVFGTPTPQHF | ||
| 225407 | TRAV26-1 | TRAJ43 | CIVRPRGDNDMRF | TRBV3-1 | TRBJ1-5 | CASSQVFGTPTPQHF | ||
| 225408 | TRAV4 | TRAJ28 | CLVGDSGAGSYQLTF | TRBV3-1 | TRBJ1-5 | CASSQVFGTPTPQHF | ||
| 225420 | TRAV38-1 | TRAJ20 | CAFRGPNDYKLSF | TRBV13 | TRBD1 | TRBJ1-6 | CASSPKGTDGNSPLHF | |
| 225581 | TRAV8-3 | TRAJ9 | CAVVVRNTGGFKTIF | TRBV12-4 | TRBD2 | TRBJ2-1 | CASTTGTSGRDYNEQFF | |
| 225581 | TRAV8-3 | TRAJ9 | CAVVVRNTGGFKTIF | TRBV12-4 | TRBD2 | TRBJ2-1 | CASTTGTSGRDYNEQFF | |
| 225581 | TRAV8-3 | TRAJ9 | CAVVVRNTGGFKTIF | TRBV12-4 | TRBD2 | TRBJ2-1 | CASTTGTSGRDYNEQFF | |
| 225581 | TRAV8-3 | TRAJ9 | CAVVVRNTGGFKTIF | TRBV12-4 | TRBD2 | TRBJ2-1 | CASTTGTSGRDYNEQFF | |
| 225622 | TRAV41 | TRAJ48 | CAVRGEFGNEKLTF | TRBV7-3 | TRBJ2-1 | CASSLLPYNEQFF | ||
| 225687 | TRAV9-2 | TRAJ49 | CALSVSNQFYF | TRBV4-1 | TRBJ2-1 | CASSRDRSSYNEQFF | ||
| 225727 | TRAV1-2 | TRAJ12 | CVLMDSSYKLIF | TRBV6-2 | TRBD1 | TRBJ2-3 | CASSTPPDRADTQYF | |
| 225739 | TRAV8-1 | TRAJ36 | CAVILTGANNLFF | TRBV11-1 | TRBJ2-3 | CASSQQRGRTDTQYF | ||
| 225742 | TRAV5 | TRAJ10 | CAEILTGGGNKLTF | TRBV11-2 | TRBJ2-3 | CASSLQTGRTDTQYF | ||
| 225742 | TRAV5 | TRAJ10 | CAEILTGGGNKLTF | TRBV11-2 | TRBJ2-3 | CASSLQTGRTDTQYF | ||
| 225815 | TRAV29/DV5 | TRAJ33 | CAARLINYQLIW | TRBV4-3 | TRBJ2-2 | CASSQDPAWGGANTGELFF | ||
| 225815 | TRAV29/DV5 | TRAJ33 | CAARLINYQLIW | TRBV4-3 | TRBJ2-2 | CASSQDPAWGGANTGELFF | ||
| 225847 | TRAV20 | TRAJ52 | CAVQAVKLGGTSYGKLTF | TRBV7-2 | TRBD1 | TRBJ2-5 | CASSAGQGGVETQYF | |
| 226027 | TRAV38-2/DV8 | TRAJ32 | CALPLHGGATNKLIF | TRBV19 | TRBJ2-6 | CAGRQAGANVLTF | ||
| 226102 | TRAV27 | TRAJ44 | CAGNTGTASKLTF | TRBV9 | TRBJ2-7 | CASSPKYSYEQYF | ||
| 226148 | TRAV19 | TRAJ24 | CALGPWGKLQF | TRBV3-1 | TRBJ2-7 | CASSQVGGSSREQYF |
相关文章
| Reference – PMID | Reference – Journal | Reference – Date | Reference – Title |
|---|---|---|---|
| 17092434 | Cell Mol Immunol | 2006 | Preparation and characterization of HLA-A*0201 tetramer loaded with IE-1316-324 antigenic peptide of human cytomegalovirus. |
| 16275592 | Biol Blood Marrow Transplant | 2005 | Cytomegalovirus immune reconstitution occurs in recipients of allogeneic hematopoietic cell transplants irrespective of detectable cytomegalovirus infection. |
| 14550813 | Exp Hematol | 2003 | A CTL epitope from human cytomegalovirus IE1 defined by combining prediction of HLA binding and proteasomal processing is the target of dominant immune responses in patients after allogeneic stem cell transplantation. |
| 12634406 | J Virol | 2003 | Use of transgenic HLA A*0201/Kb and HHD II mice to evaluate frequency of cytomegalovirus IE1-derived peptide usage in eliciting human CD8 cytokine response. |
| 11930311 | J Infect Dis | 2002 | Comparative analysis of CD8+ T cell responses against human cytomegalovirus proteins pp65 and immediate early 1 shows similarities in precursor frequency, oligoclonality, and phenotype. |
| 15619009 | Cell Mol Life Sci | 2005 | Major contribution of codominant CD8 and CD4 T cell epitopes to the human cytomegalovirus-specific T cell repertoire. |
| 17492595 | J Infect Dis | 2007 | Cytomegalovirus (CMV) IE1- and pp65-specific CD8+ T cell responses broaden over time after primary CMV infection in infants. |
| 16388983 | J Clin Virol | 2006 | Attenuated poxvirus expressing three immunodominant CMV antigens as a vaccine strategy for CMV infection. |
| 14764694 | J Immunol | 2004 | Human cytomegalovirus proteins pp65 and immediate early protein 1 are common targets for CD8+ T cell responses in children with congenital or postnatal human cytomegalovirus infection. |
| 18982061 | PLoS One | 2008 | Levels of CMV specific CD4 T cells are dynamic and correlate with CMV viremia after allogeneic stem cell transplantation. |
| 18706443 | Immunol Lett | 2008 | A novel approach to evaluate the immunogenicity of viral antigens of clinical importance in HLA transgenic murine models. |
| 14670917 | Blood | 2004 | Rapid generation of combined CMV-specific CD4+ and CD8+ T-cell lines for adoptive transfer into recipients of allogeneic stem cell transplants. |
| 22197248 | Antiviral Res | 2012 | The development of Chinese specific human cytomegalovirus polyepitope recombinant vaccine. |
| 23100361 | J Gen Virol | 2013 | Suppression of CD8+ T-cell recognition in the immediate-early phase of human cytomegalovirus infection. |
| 23267020 | J Immunol | 2013 | CD8+ TCR repertoire formation is guided primarily by the peptide component of the antigenic complex. |
| 15597326 | Eur J Immunol | 2005 | Contemporaneous fluctuations in T cell responses to persistent herpes virus infections. |
| 23717207 | PLoS Pathog | 2013 | Presentation of an immunodominant immediate-early CD8+ T cell epitope resists human cytomegalovirus immunoevasion. |
| 23748502 | Nat Biotechnol | 2013 | Combinatorial tetramer staining and mass cytometry analysis facilitate T-cell epitope mapping and characterization. |
| 24760079 | PLoS One | 2014 | Identification and HLA-tetramer-validation of human CD4+ and CD8+ T cell responses against HCMV proteins IE1 and IE2. |
| 25108651 | Cytotherapy | 2014 | Clinical-scale isolation of ‘minimally manipulated’ cytomegalovirus-specific donor lymphocytes for the treatment of refractory cytomegalovirus disease. |
| 25339770 | J Virol | 2015 | Clonal evolution of CD8+ T cell responses against latent viruses: relationship among phenotype, localization, and function. |
| 26603974 | Am J Transplant | 2016 | Virus-Specific CD8(+) T Cells Cross-Reactive to Donor-Alloantigen Are Transiently Present in the Circulation of Kidney Transplant Recipients Infected With CMV and/or EBV. |
| 26800118 | Clin Exp Immunol | 2016 | Abundant cytomegalovirus (CMV) reactive clonotypes in the CD8(+) T cell receptor alpha repertoire following allogeneic transplantation. |
| 26509579 | PLoS One | 2015 | Multiplex Identification of Antigen-Specific T Cell Receptors Using a Combination of Immune Assays and Immune Receptor Sequencing. |
| 26033882 | Cytometry A | 2015 | Design and validation of conditional ligands for HLA-B*08:01, HLA-B*15:01, HLA-B*35:01, and HLA-B*44:05. |
| 28818566 | Vaccine | 2017 | A synthetic human cytomegalovirus pp65-IE1 fusion antigen efficiently induces and expands virus specific T cells. |
| 29666167 | J Exp Med | 2018 | A flexible MHC class I multimer loading system for large-scale detection of antigen-specific T cells. |
| 26314621 | Arthritis Rheumatol | 2016 | Latent Cytomegalovirus Infection in Rheumatoid Arthritis and Increased Frequencies of Cytolytic LIR-1+CD8+ T Cells. |
| 24512815 | J Immunol Methods | 2014 | In vitro expansion of antigen-specific CD8(+) T cells distorts the T-cell repertoire. |
| 31324690 | Sci Immunol | 2019 | Empty peptide-receptive MHC class I molecules for efficient detection of antigen-specific T cells. |
| 31398327 | Cell | 2019 | T-Scan: A Genome-wide Method for the Systematic Discovery of T Cell Epitopes. |
| 32393905 | Nat Biotechnol | 2020 | Massively parallel interrogation and mining of natively paired human TCRαβ repertoires. |
| 33329532 | Front Immunol | 2020 | Cytomegalovirus-Specific T Cell Epitope Recognition in Congenital Cytomegalovirus Mother-Infant Pairs. |
| 33427749 | J Clin Invest | 2021 | SARS-CoV-2-specific CD8+ T cell responses in convalescent COVID-19 individuals. |
| 33853928 | Sci Immunol | 2021 | SARS-CoV-2 genome-wide T cell epitope mapping reveals immunodominance and substantial CD8<sup>+</sup> T cell activation in COVID-19 patients. |
| 36980230 | Cells | 2023 | Persistent CD8 T Cell Marks Caused by the HCMV Infection in Seropositive Adults: Prevalence of HLA-E-Reactive CD8 T Cells. |
| 36121440 | Blood Adv | 2023 | Tracking the progeny of adoptively transferred virus-specific T cells in patients posttransplant using TCR sequencing. |
| 37586765 | J Immunother Cancer | 2023 | TCR-engaging scaffolds selectively expand antigen-specific T-cells with a favorable phenotype for adoptive cell therapy. |
| 35401538 | Front Immunol | 2022 | Public T-Cell Receptors (TCRs) Revisited by Analysis of the Magnitude of Identical and Highly-Similar TCRs in Virus-Specific T-Cell Repertoires of Healthy Individuals. |
| 38053994 | Front Immunol | 2023 | Overall avidity declines in TCR repertoires during latent CMV but not EBV infection. |
| 38608022 | Sci Adv | 2024 | Simultaneous analysis of pMHC binding and reactivity unveils virus-specific CD8 T cell immunity to a concise epitope set. |
| 37133356 | Elife | 2023 | Improved T cell receptor antigen pairing through data-driven filtering of sequencing information from single cells. |
